In this respect, the experimental data showed that statins may prevent the oxidation of glycated LDL particles and reduce levels of atherogenic small, dense LDL [79], while the results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) trial demonstrated that atorvastatin treatment significantly reduced the levels of both glycated apoB and oxidized LDL in patients with type 2 DM [55]. This evidence concerns the gene APOB and diabetes mellitus.